AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31577715 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher AVF luminal pressure
Number of subjects: 0
Study 31577715 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted AVF maturation
Number of subjects: 0
Study 31577771 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive PSA results
Number of subjects: 1653
Study 31577771 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative PSA results
Number of subjects: 1653
Study 31577771 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient management after positive PSA value
Number of subjects: 1653
Study 31577804 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheostomy
Number of subjects: 2087
Study 31577804 — intervention group
Group type: COMPARATOR
Intervention: No Tracheostomy
Number of subjects: 2087
Study 31578012 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban treatment in patients with prior ischemic stroke/TIA
Number of subjects: 9578
Study 31578012 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban treatment in patients without prior ischemic stroke/TIA
Number of subjects: 9578
Study 31578082 — intervention group
Group type: EXPERIMENTAL
Intervention: Evinacumab
Number of subjects: 9
Study 31578311 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-corrected autologous cell therapy (transplanted epidermal sheets measuring 5 × 7 cm)
Number of subjects: 7
Study 31578311 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-corrected autologous cell therapy
Number of subjects: 7
Study 31578311 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated wounds)
Number of subjects: 7
Study 31578700 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical training tutored by an expert
Number of subjects: 172
Study 31578700 — intervention group
Group type: COMPARATOR
Intervention: Direct access to DUS examination without practical training
Number of subjects: 172
Study 31579027 — intervention group
Group type: EXPERIMENTAL
Intervention: BTG-002814 (100 mg vandetanib) delivered transarterially, 7 to 21 days before surgery
Number of subjects: 3
Study 31579027 — intervention group
Group type: EXPERIMENTAL
Intervention: BTG-002814 (100 mg vandetanib)
Number of subjects: 3
Study 31579047 — intervention group
Group type: EXPERIMENTAL
Intervention: Seismocardiograph (SCG) during breath-holding
Number of subjects: 43
Study 31579047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistocardiograph (BCG) during breath-holding
Number of subjects: 43
Study 31579047 — intervention group
Group type: EXPERIMENTAL
Intervention: Seismocardiograph (SCG) during spontaneous respiration following apnea
Number of subjects: 43
Study 31579047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of iK of diastole to systole during restoration of respiration
Number of subjects: 43
Study 31579106 — intervention group
Group type: EXPERIMENTAL
Intervention: Atlas Unicompartmental Knee System Load Absorber
Number of subjects: 26
Study 31579436 — intervention group
Group type: EXPERIMENTAL
Intervention: SVM model using target miRNA/reference miRNA ratio
Number of subjects: 59
Study 31579436 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal component analysis
Number of subjects: 59
Study 31579676 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 0
Study 31580130 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping self-efficacy
Number of subjects: 0
Study 31580386 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine plus cisplatin (25 mg/m2, 37.5 mg/m2, 50 mg/m2) on days 1 and 8 of a 21-day cycle
Number of subjects: 25
Study 31581055 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks for up to 2 years
Number of subjects: 1008
Study 31581306 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 0
Study 31581800 — intervention group
Group type: EXPERIMENTAL
Intervention: SCC DBS
Number of subjects: 28
Study 31582135 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarucizumab
Number of subjects: 503
Study 31582133 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress CMR with no ischemia or late gadolinium enhancement (LGE)
Number of subjects: 2349
Study 31582133 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress CMR with ischemia+/LGE+
Number of subjects: 2349
Study 31582133 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ischemia and LGE both negative
Number of subjects: 2349
Study 31582137 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorized hyperemic pullback pressure gradients (PPGs)
Number of subjects: 117
Study 31582202 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 300
Study 31582202 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccination
Number of subjects: 300
Study 31582202 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B virus (HBV) vaccination
Number of subjects: 300
Study 31582202 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination against all three microorganisms
Number of subjects: 300
Study 31582202 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of correct vaccination
Number of subjects: 300
Study 31582202 — intervention group
Group type: EXPERIMENTAL
Intervention: Sick leaves due to flu
Number of subjects: 300
Study 31582202 — intervention group
Group type: EXPERIMENTAL
Intervention: Lost working days due to flu
Number of subjects: 300
Study 31582202 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalizations due to flu
Number of subjects: 300
Study 31582553 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90-labeled anti-CD45 antibody followed by fludarabine and 2 Gy total body irradiation prior to hematopoietic cell transplantation
Number of subjects: 15
Study 31582673 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy in SP group (67.5% prescribed)
Number of subjects: 1868
Study 31582673 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy in PP group (30.1% prescribed)
Number of subjects: 1868
Study 31582673 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol levels in SP group (18% at recommended level)
Number of subjects: 1868
Study 31582673 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol levels in PP group (10.6% at recommended level)
Number of subjects: 1868
Study 31582673 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of high cholesterol levels in SP and PP groups
Number of subjects: 1868
Study 31582673 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for treatment discontinuation
Number of subjects: 1868
Study 31582991 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfragmented dermal extract obtained with Rigenera™ technology
Number of subjects: 0
Study 31582991 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31583112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) device (LymphAssist, Huntleigh Healthcare)
Number of subjects: 20
Study 31583112 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 31583172 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanted seizure prediction system (NCT01043406)
Number of subjects: 0
Study 31583331 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 48
Study 31583331 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 48
Study 31583470 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor air quality indices (CO)
Number of subjects: 0
Study 31583561 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraphysiologic doses of levothyroxine (L-T4)
Number of subjects: 0
Study 31583561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31584000 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT (internet-based cognitive behavioral therapy) program for 9 weeks
Number of subjects: 144
Study 31584000 — intervention group
Group type: COMPARATOR
Intervention: ODF (online discussion forum)
Number of subjects: 144
Study 31584004 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated wellness care clinics and SHIELD intervention
Number of subjects: 0
Study 31584004 — intervention group
Group type: EXPERIMENTAL
Intervention: Only SHIELD intervention
Number of subjects: 0
Study 31584004 — intervention group
Group type: COMPARATOR
Intervention: Control zones with no intervention
Number of subjects: 0
Study 31584094 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal malaria chemoprevention (SMC)
Number of subjects: 0
Study 31584094 — intervention group
Group type: COMPARATOR
Intervention: Control (no SMC)
Number of subjects: 0
Study 31584608 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg twice daily in c-MET ≥6 copies cohort
Number of subjects: 90
Study 31584608 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg twice daily in c-MET mutation cohort
Number of subjects: 90
Study 31584608 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg twice daily in ROS-1 translocation cohort
Number of subjects: 90
Study 31584770 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective period for any hypoglycemia (T1D)
Number of subjects: 664
Study 31584770 — intervention group
Group type: COMPARATOR
Intervention: Retrospective period for any hypoglycemia (T1D)
Number of subjects: 664
Study 31584770 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective period for any hypoglycemia (T2D)
Number of subjects: 664
Study 31584770 — intervention group
Group type: COMPARATOR
Intervention: Retrospective period for any hypoglycemia (T2D)
Number of subjects: 664
Study 31584770 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective period for severe hypoglycemia (T1D)
Number of subjects: 664
Study 31584770 — intervention group
Group type: COMPARATOR
Intervention: Retrospective period for severe hypoglycemia (T1D)
Number of subjects: 664
Study 31584770 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective period for severe hypoglycemia (T2D)
Number of subjects: 664
Study 31584770 — intervention group
Group type: COMPARATOR
Intervention: Retrospective period for severe hypoglycemia (T2D)
Number of subjects: 664
Study 31585005 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral (DAA) therapy
Number of subjects: 402
Study 31585012 — intervention group
Group type: EXPERIMENTAL
Intervention: PLMS with arousal
Number of subjects: 49
Study 31585012 — intervention group
Group type: EXPERIMENTAL
Intervention: Arousals associated with PLMS
Number of subjects: 49
Study 31585012 — intervention group
Group type: COMPARATOR
Intervention: PLMS without arousal
Number of subjects: 49
Study 31585957 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) and selective hedgehog pathway inhibitor vismodegib
Number of subjects: 1
Study 31586174 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers' illness representations (IRs) aligned with the professional model of asthma management.
Number of subjects: 267
Study 31586174 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural equation model results.
Number of subjects: 267
Study 31586174 — intervention group
Group type: EXPERIMENTAL
Intervention: Social/contextual predictors of asthma illness representations (IRs).
Number of subjects: 267
Study 31586493 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater GLP-1 response
Number of subjects: 837
Study 31586493 — intervention group
Group type: COMPARATOR
Intervention: Greatest quartile of GLP-1 response
Number of subjects: 837
Study 31586664 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent cetuximab (400 mg/m2) and intensity modulated radiation therapy with carbon ion boost
Number of subjects: 23
Study 31586667 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin
Number of subjects: 0
Study 31586757 — intervention group
Group type: EXPERIMENTAL
Intervention: Glembatumumab vedotin (GV) 1.9 mg/kg/dose administered on day 1 of each 21 day cycle.
Number of subjects: 22
Study 31586757 — intervention group
Group type: EXPERIMENTAL
Intervention: Glembatumumab vedotin (GV)
Number of subjects: 22
Study 31586998 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in patients <70 years old
Number of subjects: 866
Study 31586998 — intervention group
Group type: COMPARATOR
Intervention: Treatment in patients ≥70 years old
Number of subjects: 866
Study 31586998 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival in patients <70 years old
Number of subjects: 866
Study 31586998 — intervention group
Group type: COMPARATOR
Intervention: Overall survival in patients ≥70 years old
Number of subjects: 866
Study 31586998 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a factor in overall survival
Number of subjects: 866
Study 31587120 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography (EIT) measures during PEEP trials
Number of subjects: 0
Study 31587120 — intervention group
Group type: EXPERIMENTAL
Intervention: Different EIT measures
Number of subjects: 0
Study 31587882 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazertinib (20 mg, 40 mg, 80 mg, 120 mg, 160 mg, 240 mg, or 320 mg once daily continuously in 21-day cycles)
Number of subjects: 127
Study 31587882 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazertinib
Number of subjects: 127
Study 31588013 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion (BPD)
Number of subjects: 0
Study 31588013 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 0
Study 31588425 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal iron distribution
Number of subjects: 0
Study 31588425 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection susceptibility
Number of subjects: 0
Study 31588425 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31588493 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg liposomal amphotericin B
Number of subjects: 16
Study 31588493 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg liposomal amphotericin B
Number of subjects: 16
Study 31588493 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose of 300 or 500 mg liposomal amphotericin B for patients ≥100 kg
Number of subjects: 16
Study 31588494 — intervention group
Group type: EXPERIMENTAL
Intervention: Liothyronine every 8 hours for 2 weeks (n = 7)
Number of subjects: 7
Study 31588494 — intervention group
Group type: EXPERIMENTAL
Intervention: Liothyronine after 6 months (n = 4)
Number of subjects: 7
Study 31588567 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 mg plus low-dose dexamethasone (40 mg or 20 mg for patients aged >75 years)
Number of subjects: 56
Study 31588660 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPROD bpMRI Likert score
Number of subjects: 80
Study 31588660 — intervention group
Group type: COMPARATOR
Intervention: Clinical variables
Number of subjects: 80
Study 31588660 — intervention group
Group type: COMPARATOR
Intervention: mRNA biomarkers
Number of subjects: 80
Study 31588660 — intervention group
Group type: COMPARATOR
Intervention: Additional IMPROD bpMRI parameters
Number of subjects: 80
Study 31588660 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clinical and mRNA biomarkers
Number of subjects: 80
Study 31588660 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative IMPROD bpMRI Likert score
Number of subjects: 80
Study 31588864 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate challenge
Number of subjects: 72
Study 31588872 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised endurance training for 10 weeks
Number of subjects: 0
Study 31589281 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Priorities Care (PPC)
Number of subjects: 366
Study 31589281 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 366
Study 31589465 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 3202
Study 31589465 — intervention group
Group type: EXPERIMENTAL
Intervention: Black patients
Number of subjects: 3202
Study 31589465 — intervention group
Group type: EXPERIMENTAL
Intervention: Other nonwhite patients
Number of subjects: 3202
Study 31589465 — intervention group
Group type: EXPERIMENTAL
Intervention: Education level
Number of subjects: 3202
Study 31589625 — intervention group
Group type: EXPERIMENTAL
Intervention: e-partograph
Number of subjects: 1012
Study 31589625 — intervention group
Group type: COMPARATOR
Intervention: paper partograph
Number of subjects: 1012
Study 31590067 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Gait Index (DGI)
Number of subjects: 32
Study 31590634 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive performance assessment in patients with sufficient performance validity (239 patients)
Number of subjects: 279
Study 31590634 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive performance assessment in patients with insufficient performance validity (40 patients)
Number of subjects: 279
Study 31590634 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report questionnaires administered to measure cognitive complaints, fatigue, anxiety, depressive symptoms
Number of subjects: 279
Study 31590634 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of cognitive test scores to a normative sample
Number of subjects: 279
Study 31590677 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 54
Study 31590677 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalization algorithm using clinical pretreatment data
Number of subjects: 54
Study 31591361 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic diagnosis of Endometrial Hyperplasia (EH) by senior gynecologists
Number of subjects: 0
Study 31591599 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal microbiome transplantation (VMT) from healthy donors
Number of subjects: 5
Study 31591636 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy (ET)
Number of subjects: 4262
Study 31591636 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT)
Number of subjects: 4262
Study 31591636 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy (ET) in postmenopausal patients
Number of subjects: 4262
Study 31591636 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) in premenopausal patients
Number of subjects: 4262
Study 31591739 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose decitabine
Number of subjects: 0
Study 31592575 — intervention group
Group type: EXPERIMENTAL
Intervention: Health insurance
Number of subjects: 0
Study 31592575 — intervention group
Group type: COMPARATOR
Intervention: Uninsured participants
Number of subjects: 0
Study 31592575 — intervention group
Group type: EXPERIMENTAL
Intervention: Insured participants
Number of subjects: 0
Study 31592575 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age and STI diagnosis
Number of subjects: 0
Study 31592772 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based aerobic and strengthening exercises during preoperative chemotherapy or chemoradiation
Number of subjects: 50
Study 31592894 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 5577
Study 31592894 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 5577
Study 31592894 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RYGB and SG
Number of subjects: 5577
Study 31592901 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermochromic nail polish
Number of subjects: 50
Study 31592900 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexor hallucis brevis
Number of subjects: 60
Study 31592900 — intervention group
Group type: COMPARATOR
Intervention: Adductor pollicis
Number of subjects: 60
Study 31593308 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg/day for a minimum of 9 days, mean 13.6 days)
Number of subjects: 36
Study 31593308 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 36
Study 31593552 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-16 overexpression
Number of subjects: 0
Study 31593552 — intervention group
Group type: EXPERIMENTAL
Intervention: EVs from MM-PCs with Del13
Number of subjects: 0
Study 31593552 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-15a-16-1-KO mouse model
Number of subjects: 0
Study 31593563 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic Leishmania infection detected using DAT, rK39-RDT, PCR, and KAtex urine antigen test.
Number of subjects: 511
Study 31593563 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of prevalent infections.
Number of subjects: 511
Study 31593563 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study follow-up.
Number of subjects: 511
Study 31594030 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31594647 — intervention group
Group type: EXPERIMENTAL
Intervention: ACHIM (anaerobic cultivated human intestinal microbiota) administered via upper gastrointestinal route using endoscopy for 10 days
Number of subjects: 50
Study 31594667 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) treatment
Number of subjects: 460
Study 31594667 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir/velpatasvir (SOF/VEL)
Number of subjects: 460
Study 31594667 — intervention group
Group type: COMPARATOR
Intervention: Glecaprevir/pibrentasvir (GLE/PIB)
Number of subjects: 460
Study 31594667 — intervention group
Group type: COMPARATOR
Intervention: Ledipasvir/sofosbuvir (LDV/SOF)
Number of subjects: 460
Study 31594705 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone
Number of subjects: 211
Study 31594705 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide
Number of subjects: 211
Study 31595258 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing care intervention centered on basic self-care including twice daily walking training, privileging pre-established trips to the toilet by walking, and all daytime meals seated, off the bed.
Number of subjects: 182
Study 31595258 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 182
Study 31595259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program comprising 3 weekly classes of physical exercise (45/50 min each) delivered by trained teachers after teachers' training by researchers.
Number of subjects: 410